Iterum Therapeutics (ITRMF) files Form 25 to remove Ordinary Shares from Nasdaq
Filing Impact
Filing Sentiment
Form Type
25-NSE
Rhea-AI Filing Summary
Iterum Therapeutics plc notified Nasdaq of the removal of its Ordinary Shares from listing and/or registration on the Nasdaq Stock Market LLC pursuant to Form 25 and the cited rules 17 CFR 240.12d2-2. The Exchange certified compliance with its procedures for withdrawal.
Positive
- None.
Negative
- None.
Key Figures
Commission File Number: 333-224582
Cited Rule: 17 CFR 240.12d2-2
Expires: March 31, 2018
+1 more
4 metrics
Commission File Number
333-224582
Form 25 cover filing identifier
Cited Rule
17 CFR 240.12d2-2
Regulatory provision governing removal/withdrawal
Expires
March 31, 2018
form header expiration date
Issuer telephone
312-778-6070
Issuer principal office contact
Key Terms
Form 25, 17 CFR 240.12d2-2, voluntary withdrawal
3 terms
Form 25 regulatory
"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"
A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.
17 CFR 240.12d2-2 regulatory
"Pursuant to 17 CFR 240.12d2-2(a)(1)"
A U.S. Securities and Exchange Commission rule that describes the conditions and procedural steps for a security to be removed from public registration or reporting under the Securities Exchange Act of 1934. For investors, it matters because it explains when a company’s shares can stop being subject to regular disclosure and exchange listing rules — similar to knowing when a publicly tracked product will be discontinued and no longer send updates, which affects transparency and liquidity.
voluntary withdrawal regulatory
"the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal"
FAQ
Why did Iterum Therapeutics (ITRMF) file a Form 25 with Nasdaq?
The filing notifies Nasdaq of the removal of Iterum Therapeutics plc Ordinary Shares from listing and/or registration. It cites compliance with 17 CFR 240.12d2-2 and states both the Exchange and issuer complied with rules governing voluntary withdrawal.
Does the Form 25 mean Iterum (ITRMF) is delisting by force or voluntarily?
The Form 25 states the withdrawal was processed under 17 CFR 240.12d2-2(c), indicating the issuer complied with Exchange rules governing voluntary withdrawal. The Exchange certified it followed its procedures for striking the class from listing.
Who certified the removal of Iterum Therapeutics (ITRMF) from Nasdaq?
Nasdaq Stock Market LLC certified the removal and caused the notification to be signed on its behalf by Aravind Menon, Hearings Advisor. The filing affirms Nasdaq had reasonable grounds to file Form 25 and that procedural requirements were met.
What securities class did Iterum Therapeutics (ITRMF) remove from Nasdaq?
The Form 25 identifies the class as Ordinary Shares. The Exchange states it struck that class from listing and/or withdrew its registration on Nasdaq in accordance with the cited regulatory provisions.